AI assistant
Sending…
GENTEX CORP — Director's Dealing 2020
Nov 20, 2020
30893_dirs_2020-11-20_aee1f11d-e99f-4ccb-a022-e942ac6d61cb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GENTEX CORP (GNTX)
CIK: 0000355811
Period of Report: 2020-11-18
Reporting Person: Boehm Neil (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-11-18 | Common Stock | M | 15000.00 | $22.94 | Acquired | 47578.00 | Direct |
| 2020-11-18 | Common Stock | M | 4968.00 | $15.69 | Acquired | 52546.00 | Direct |
| 2020-11-18 | Common Stock | S | 19968.00 | $33.224 | Disposed | 32578.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-11-18 | Employee Stock Option (Right to buy) | $22.94 | M | 15000.00 | Disposed | 2028-02-15 | Common Stock (15000.00) | Direct |
| 2020-11-18 | Employee Stock Option (Right to buy) | $15.69 | M | 4968.00 | Disposed | 2021-03-31 | Common Stock (4968.00) | Direct |
Footnotes
F1: Column 5 reflects the acquisition of 31 shares under the Gentex Corp. Employee Stock Purchase Plan.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F3: This transaction was executed in multiple trades at prices ranging from $33.15 to $33.32. The price reported above reflects the weighted average price.
F4: These shares become exercisable as to 25% one year after date of grand and an additional 25% at each ensuing anniversary date.
More from GENTEX CORP
Interim / Quarterly Report
2026
May 6
Major Shareholding Notification
2026
Apr 30
Regulatory Filings
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 9
Proxy Solicitation & Information Statement
2026
Apr 9
Major Shareholding Notification
2026
Mar 26
Annual Report
2026
Feb 24
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19